{
    "id": "3f4e5db8-5bfb-4b24-8465-9757cbaad2be",
    "indications": {
        "text": "fenofibrate peroxisome proliferator-activated receptor ( ppar ) alpha agonist indicated adjunct diet \u2022 reduce elevated ldl-c , total-c , tg apo b , increase hdl- c adult patients primary hypercholesterolemia mixed dyslipidemia ( 1.1 ) . \u2022 treatment adult patients severe hypertriglyceridemia ( 1.2 ) . limitations : fenofibrate shown reduce coronary heart disease morbidity mortality patients type 2 diabetes mellitus ( 5.1 ) .",
        "doid_entities": [
            {
                "text": "dyslipidemia (DOID:3146)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3146"
            },
            {
                "text": "coronary heart disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 primary hypercholesterolemia mixed dyslipidemia : initial dose 160 mg daily ( 2.2 ) . \u2022 severe hypertriglyceridemia : initial dose 54 160 mg daily . maximum dose 160 mg ( 2.3 ) . \u2022 renally impaired patients : initial dose 54 mg daily ( 2.4 ) . \u2022 geriatric patients : select dose basis renal function ( 2.5 ) \u2022 given meals ( 2.1 ) .",
        "doid_entities": [
            {
                "text": "dyslipidemia (DOID:3146)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3146"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "fenofibrate tablets , usp available two strengths : 160 mg white white , oval shaped , film coated tablets debossed `` ls `` one side `` 215 `` side cartons 30 film coated tablets ( 10 film coated tablets blister pack x 3 ) , ndc 0904-7539-04 warning : unit dose package child resistant intended institutional . keep drugs reach children . storage store 20\u00b0c 25\u00b0c [ 68\u00b0f 77\u00b0f ] [ usp controlled room temperature ] . keep reach children . protect moisture .",
    "adverseReactions": "fenofibrate tablet contraindicated : \u2022patients severe renal impairment , including receiving dialysis [ pharmacology ( 12.3 ) ] . \u2022patients active liver disease , including primary biliary cirrhosis unexplained persistent liver function abnormalities [ ( 5.2 ) ] \u2022patients preexisting gallbladder disease [ ( 5.5 ) ] . \u2022nursing mothers [ ( 8.2 ) ] \u2022patients known hypersensitivity fenofibrate fenofibric acid [ ( 5.9 ) ] .",
    "ingredients": [
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5001"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        }
    ],
    "organization": "Major Pharmaceuticals",
    "name": "FENOFIBRATE",
    "effectiveTime": "20250522",
    "indications_original": "Fenofibrate is peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet \u2022 To reduce elevated LDL-C, Total-C, TG and      Apo B, and to increase HDL- C in adult patients with primary      hypercholesterolemia or mixed dyslipidemia ( 1.1 ). \u2022 For treatment of adult patients with      severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ).",
    "contraindications_original": "\u2022 Primary hypercholesterolemia or mixed      dyslipidemia: Initial dose of 160 mg once daily ( 2.2 ). \u2022 Severe hypertriglyceridemia: Initial dose      of 54 to 160 mg once daily. Maximum dose is 160 mg ( 2.3 ). \u2022 Renally impaired patients: Initial dose      of 54 mg once daily ( 2.4 ). \u2022 Geriatric patients: Select the dose on      the basis of renal function ( 2.5 ) \u2022 Should be given with meals ( 2.1 ).",
    "warningsAndPrecautions_original": "Fenofibrate tablets, USP are available in two strengths:\n                  160 mg white to off white, oval shaped, film coated tablets debossed with \"LS\" on one side and \"215\" on the other side \n                  Cartons of 30 film coated tablets (10 film coated tablets each blister pack x 3), NDC 0904-7539-04\n                  WARNING: This Unit Dose package is not child resistant and is Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.\n                  \n                     Storage\n                  \n                  Store at 20\u00b0C to 25\u00b0C [68\u00b0F to 77\u00b0F] [See USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture.",
    "adverseReactions_original": "Fenofibrate tablet is contraindicated in: \n                  \n                     \n                        \u2022patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)] .\n                     \n                        \u2022patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.2)]\n                     \n                     \n                        \u2022patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)] .\n                     \n                        \u2022nursing mothers [see Use in Specific Populations (8.2)]\n                     \n                     \n                        \u2022patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions (5.9)].",
    "drug": [
        {
            "name": "FENOFIBRATE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5001"
        }
    ]
}